爱德华兹生命科学:2024年业绩符合市场预期 关注新品放量

中金公司
17 Feb

2024 年业绩符合市场预期公司公布2024 全年业绩:剔除剥离业务后,收入54.40 亿美元,同比+8.6%;经调整EPS 2.43 美元,2023 年同口径为2.22 美元。2024 年业绩符合市场预期。发展趋势TAVR 业务步入个位数增长区间,关注适应症拓展和新品研发进展。2024全年,TAVR(经导管主动脉瓣置换)收入41.06 亿美元,同比+6%;其中4 季度收入10.36 亿美元,环比...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10